Fig 1.
Flow diagram for inclusion and exclusion of studies.
ESMO: European Society for Medical Oncology; ASCO: American Society of Clinical Oncology; AACR: American Association for Cancer Research.
Table 1.
Characteristic of nine included trials.
Table 2.
Medium follow-up, objective response rate, medium progression-free survival and overall survival of included trials.
Fig 2.
Risk of bias for selected studies.
Fig 3.
Forest plot of pooled hazard ratio for progression-free survival (PFS) in CDK 4/6 inhibitors plus endocrine combination therapy and endocrine monotherapy.
SE: standard error; CDK 4/6i: CDK 4/6 inhibitors; ET: endocrine therapy.
Fig 4.
Forest plot of hazard ratio for progression-free survival (PFS) by subgroup analysis in CDK 4/6 inhibitors plus endocrine combination therapy and endocrine monotherapy.
ET: endocrine therapy; AI: aromatase inhibitors; CT: chemotherapy; PR: progesterone receptor; DFI: disease-free interval.
Fig 5.
Forest plot of hazard ratio for progression-free survival (PFS) for Asian and non-Asian subgroups in CDK 4/6 inhibitors plus endocrine combination therapy and endocrine monotherapy.
Fig 6.
Forest plot of pooled hazard ratio for overall survival (OS) in CDK 4/6 inhibitors plus endocrine combination therapy and endocrine monotherapy.
Fig 7.
Forest plot of hazard ratio for overall survival (OS) by subgroup analysis in CDK 4/6 inhibitors plus endocrine combination therapy and endocrine monotherapy.
Fig 8.
Forest plot of hazard ratio for overall survival (OS) for Asian and non-Asian subgroups in CDK 4/6 inhibitors plus endocrine combination therapy and endocrine monotherapy.
Fig 9.
Forest plot of pooled relative risk for objective response rate (ORR) in CDK 4/6 inhibitors plus endocrine combination therapy and endocrine monotherapy.
Fig 10.
Forest plot of pooled relative risk for clinical benefit rate (CBR) in CDK 4/6 inhibitors plus endocrine combination therapy and endocrine monotherapy.
Fig 11.
Forest plot of pooled relative risk for grade 3/4 adverse events (AEs) in CDK 4/6 inhibitors plus endocrine combination therapy and endocrine monotherapy (A). Relative risk for grade 3/4 adverse events (AEs) by subgroup in type of CDK inhibitors between two treatment groups (B).
Fig 12.
Forest plot of pooled relative risk for hematology toxicities (neutropenia, leukopenia, anemia) in CDK 4/6 inhibitors plus endocrine combination therapy and endocrine monotherapy.